Orazio Vittorio Multi-Omics Conference 2024

Orazio Vittorio

A/Prof Vittorio is an internationally recognised cancer biologist with a strong track record in elucidating the mechanisms of action of anti-cancer therapeutics in paediatric malignancies. He is a Scientia Associate Professor in the School of Biomedical Sciences at the University of New South Wales (UNSW), Sydney, and Head of the Metal Targeted Therapy & Immunology Laboratory. A/Prof Vittorio has authored over 120 peer-reviewed publications in leading international journals (Hindex=43), contributed six book chapters, and is an inventor on six patents. Three of his publications are recognised as ISI Highly Cited Papers. Over the past 10 years, he has secured more than $15M in competitive research funding to support innovative childhood cancer research. His expertise spans cell and molecular biology, immunology, nanomedicine, and PET imaging. His research program is internationally recognised for pioneering discoveries in copper metabolism and homeostasis in cancer. A/Prof Vittorio was the first to demonstrate that neuronal tumour cells accumulate significantly higher intracellular copper levels than non-malignant cells, a world-first finding that has underpinned the development of novel copper-targeted therapeutics for neuroblastoma and gliomas. His work on the pharmacokinetics of copper chelation therapies led to the development of a ^64CuCl₂-based PET imaging strategy, which subsequently inspired the GE Healthcare PET imaging program for solid tumours. More recently, A/Prof Vittorio made the seminal discovery that copper regulates tumour immune evasion through control of PD-L1 expression (Voli et al., Cancer Research, 2020), establishing a new mechanistic link between metal homeostasis and cancer immunology. Building on this work, his laboratory identified a strategy to significantly enhance the efficacy of anti-GD2 immunotherapy in neuroblastoma. This discovery, published in Nature Communications (2024), has been rapidly translated and is now incorporated into the international BEACON-2 clinical trial, underscoring his ability to drive discoveries from bench to bedside. A/Prof Vittorio’s recent investigations focus on the role of copper metabolism in the progression and therapeutic resistance of aggressive childhood cancers, including neuroblastoma, lower-grade glioma, diffuse intrinsic pontine glioma (DIPG), and glioblastoma. His contributions have been recognised through multiple prestigious awards, including the Cancer Institute NSW Outstanding Career Development Fellowship (2020), the Young Tall Poppy Science Award (2021), and Cure Cancer Australia Researcher of the Year (2022). As evidence of his international standing, A/Prof Vittorio has delivered over 10 invited presentations and keynote lectures, including at France Nanotech (2018), the Metals in Medicine Gordon Research Conference (2026), and Copper in Medicine, Sorrento (2024). He is an active member of the Cooperative Trials Group for Neuro-Oncology (COGNO) and the European SIOP Neuroblastoma Group, reflecting his strong commitment to multidisciplinary collaboration with clinicians and industry partners to translate innovative therapies and diagnostics into clinical practice.

Abstracts this author is presenting: